RRoche Read More Roche’s Tecentriq Cuts Death Risk 41% in ctDNA‑guided MIBC2026-02-17 Roche (OTCQX: RHHBY) reported positive phase III IMvigor011 results for Tecentriq (atezolizumab) as…